- Home
- INM vs CDT Comparison
INM vs CDT Comparison
Compare INM & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- CDT
- Stock Information
- Founded
- INM 1981
- CDT 2019
- Country
- INM Canada
- CDT United States
- Employees
- INM N/A
- CDT N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- INM Health Care
- CDT Health Care
- Exchange
- INM Nasdaq
- CDT Nasdaq
- Market Cap
- INM 4.4M
- CDT 4.6M
- IPO Year
- INM N/A
- CDT N/A
- Fundamental
- Price
- INM $2.13
- CDT $0.80
- Analyst Decision
- INM
- CDT
- Analyst Count
- INM 0
- CDT 0
- Target Price
- INM N/A
- CDT N/A
- AVG Volume (30 Days)
- INM 42.3K
- CDT 160.1K
- Earning Date
- INM 09-29-2025
- CDT 08-14-2025
- Dividend Yield
- INM N/A
- CDT N/A
- EPS Growth
- INM N/A
- CDT N/A
- EPS
- INM N/A
- CDT N/A
- Revenue
- INM $4,920,990.00
- CDT N/A
- Revenue This Year
- INM N/A
- CDT N/A
- Revenue Next Year
- INM N/A
- CDT N/A
- P/E Ratio
- INM N/A
- CDT N/A
- Revenue Growth
- INM N/A
- CDT N/A
- 52 Week Low
- INM $1.72
- CDT $1.16
- 52 Week High
- INM $8.27
- CDT $274.80
- Technical
- Relative Strength Index (RSI)
- INM 37.30
- CDT 16.72
- Support Level
- INM $2.03
- CDT $1.47
- Resistance Level
- INM $2.25
- CDT $1.36
- Average True Range (ATR)
- INM 0.08
- CDT 0.11
- MACD
- INM 0.00
- CDT -0.03
- Stochastic Oscillator
- INM 34.48
- CDT 1.24
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.